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After Adjuvant Trastuzumab Therapy for Breast Cancer
Objectives The purpose of this study was to estimate heart failure (HF) and cardiomyopathy (CM) rates after adjuvant tras-
tuzumab therapy and chemotherapy in a population of older women with early-stage breast cancer.
Background Newer biologic therapies for breast cancer such as trastuzumab have been reported to increase HF and CM in clinical
trials, especially in combination with anthracycline chemotherapy. Elderly patients, however, typically have a higher
prevalence of cardiovascular risk factors and have been underrepresented in trastuzumab clinical trials.
Methods Using Surveillance, Epidemiology, and End Results-Medicare data from 2000 through 2007, we identified
women 67 to 94 years of age with early-stage breast cancer. We calculated 3-year incidence rates of HF or CM
for the following mutually exclusive treatment groups: trastuzumab (with or without nonanthracycline chemo-
therapy), anthracycline plus trastuzumab, anthracycline (without trastuzumab and with or without nonanthracy-
cline chemotherapy), other nonanthracycline chemotherapy, or no adjuvant chemotherapy or trastuzumab ther-
apy. HF or CM events were ascertained from administrative Medicare claims. Poisson regression was used to quantify
risk of HF or CM, adjusting for sociodemographic factors, cancer characteristics, and cardiovascular conditions.
Results We identified 45,537 older women (mean age: 76.2 years, standard deviation: 6.2 years) with early-stage breast
cancer. Adjusted 3-year HF or CM incidence rates were higher for patients receiving trastuzumab (32.1 per 100
patients) and anthracycline plus trastuzumab (41.9 per 100 patients) compared with no adjuvant therapy (18.1
per 100 patients, p  0.001). Adding trastuzumab to anthracycline therapy added 12.1, 17.9, and 21.7 HF or
CM events per 100 patients over 1, 2, and 3 years of follow-up, respectively.
Conclusions HF or CM are common complications after trastuzumab therapy for older women, with higher rates than those
reported from clinical trials. (J Am Coll Cardiol 2012;60:2504–12) © 2012 by the American College of Cardiology
FoundationMany cancer therapies confer an increased risk of adverse
cardiac outcomes such as heart failure (HF) and cardiomy-
opathy (CM) (1). Such cardiotoxicity is of particular con-
cern for patients undergoing adjuvant therapy for breast
cancer, because several widely used drugs can cause abnor-
malities in left ventricular function, leading to HF or CM.
Anthracycline is a common breast cancer therapy that
increases the risk of HF or CM (2,3), which then can persist
many years after the conclusion of chemotherapy (4).
See page 2513
Newer biologic therapies, such as the monoclonal anti-
body trastuzumab, also may cause cardiotoxicity. Trastu-
zumab is used to treat breast tumors that overexpress human
pidermal growth factor receptor-2 and improves disease-free
nd overall survival, but at increased risk of cardiotoxicity (5–7).
ooled data from randomized clinical trials estimate that
rastuzumab is associated with an absolute increase in HF
ncidence by 1.6% and abnormalities in left ventricular systolic
unction by 7.2% (8). However, clinical trials of trastuzumab
ypically have enrolled younger women without cardiac
omorbidities (5–7); in fact, 1 trastuzumab trial excluded
atients older than 70 years because of concerns over its
afety profile (7). Single-center studies suggest that the risk
f HF or CM is substantially higher for older patients: a
tudy of women 70 years of age or older that reported 26.7%
f patients (12 of 45) had HF or an asymptomatic decline inleft ventricular ejection fraction (LVEF) after trastuzumab
therapy over a median duration of 49 weeks (9).
Because 40.8% of women diagnosed with breast cancer in
the United States are at least 65 years of age (10) and
because risk for cardiovascular events increases with age, it is
crucial to understand better the risk of cardiotoxicity asso-
ciated with trastuzumab and chemotherapy in older adults
outside of clinical trials. Given the increasing number of
long-term breast cancer survivors exposed to newer breast
cancer therapies with the potential for myocardial injury,
preventing and managing cancer therapy-induced cardio-
toxicity represent an important point of collaboration be-
tween oncologists and cardiologists to reduce the burden of
HF and CM (11,12). Our study sought to focus on
outcomes of HF and CM, the most serious cardiotoxic
complications associated with breast cancer therapy. Ac-
cordingly, we analyzed data from the Surveillance, Epide-
miology, and End Results (SEER)-Medicare linked data-
base to evaluate the use of adjuvant trastuzumab and
anthracycline therapy in older women with early-stage
breast cancer and the relationship between these cancer
therapies with development of HF or CM.
Methods
Data Sources
SEER-Medicare is a database consisting of patient de-
mographics and cancer characteristics from 16 tumor
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Heart Failure and Cardiomyopathy After Trastuzumab December 18, 2012:2504–12registries linked to Medicare
claims that include date of ser-
vice, diagnoses, and procedures
(including biologic therapy and
chemotherapy) from care billed
by hospitals, outpatient facilities,
and physicians. This database is a
collaboration between the Na-
tional Cancer Institute, SEER,
and the Centers for Medicare and
Medicaid Services (13).
Study Cohort
Breast cancer cohort. We se-
lected women with an initial pri-
mary diagnosis of invasive breast
cancer from 2000 through 2007
in SEER with Medicare claims
available from 1998 through
2009. We included only patients who were at least 67 years
old at the time of their breast cancer diagnosis to ensure a
minimum of 2 years of Medicare claims from which to
ascertain comorbidities. To identify patients eligible for
adjuvant therapy, the cohort consisted of women with early
breast cancer (stages I through III) who underwent breast
cancer surgery as per Medicare claims (Online Appendix).
Patients were excluded if: 1) breast cancer was not the initial
primary tumor diagnosis reported to SEER, or Medicare
claims indicated any cancer diagnosis in Medicare claims
within 2 years before the index diagnosis of breast cancer; 2)
the source of diagnosis was autopsy or death certificate;
3) tumor histological examination was not of epithelial origin
(Online Appendix) or stage was unknown; 4) month of
diagnosis was missing or the patient died during the month of
diagnosis; 5) patients did not have continuous fee-for-service
Medicare Part A or Part B coverage or at least 1 nondenied
Medicare claim during the 2 years before diagnosis through the
end of the study period; or 6) chemotherapy or trastuzumab
therapy was initiated more than 9 months after breast cancer
surgery. Because the intent of our study was to identify incident
cardiac events that potentially were attributable to cancer
therapy, we excluded patients with a prior inpatient HF or CM
Medicare claim or with 2 or more HF or CM outpatient or
physician claims more than 30 days apart within 2 years before
the diagnosis of breast cancer.
Cancer-free Medicare cohort. To compare HF or CM
rates in our study’s reference group (SEER-Medicare pa-
tients with breast cancer who did not receive adjuvant
chemotherapy or trastuzumab) with those of the general
Medicare population, we assembled a cohort of female
Medicare beneficiaries with no known history of cancer.
From the standard 5% Medicare sample, we performed a
1:1 match of female patients without a history of cancer to
SEER-Medicare patients who did not receive any adjuvant
chemotherapy or trastuzumab therapy, matching on the
Abbreviations
and Acronyms
AT  anthracycline plus
trastuzumab
CI  confidence interval
CM  cardiomyopathy
HF  heart failure
ICD-9-CM  International
Classification of Disease-
9th Revision-Clinical
Modification
IRR  incidence rate ratio
LVEF  left ventricular
ejection fraction
SEER  Surveillance,
Epidemiology, and End
Resultsfollowing characteristics: 1) SEER region of residence; c2) age quartile; 3) number of Elixhauser comorbidities (14)
(any vs. none); and 4) quartile of total Medicare costs during
the year preceding cancer diagnosis (or the year preceding
index date for cancer-free individuals). For cancer-free
patients, we selected a random index date within the same
calendar year as the diagnosis of cancer of the matched
SEER patient.
Chemotherapy and trastuzumab therapy. Receipt of adjuvant
chemotherapy and trastuzumab were identified on the basis
of the Healthcare Common Procedure Coding System
codes (15) (Online Appendix) from Medicare claims billed
in the first 12 months after breast cancer surgery. Patients were
assigned to the following mutually exclusive treatment groups: 1)
trastuzumab (with or without nonanthracycline chemotherapy); 2)
anthracycline plus trastuzumab (AT); 3) anthracycline (without
rastuzumab and with or without nonanthracycline chemother-
py); 4) other (nonanthracycline) chemotherapy; or 5) no adjuvant
hemotherapy or trastuzumab therapy.
F or CM outcomes. Cardiotoxicity outcomes of interest
ncluded claims with HF or CM diagnoses according to the
ollowing International Classification of Disease, 9th Revi-
ion, Clinical Modification (ICD-9-CM) codes: HF
402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.93,
28.x) or CM (425.x). As recommended by current algo-
ithms, only ICD-9-CM diagnosis codes that appeared in at
east 1 inpatient claim or 2 outpatient or physician claims at
east 30 days apart were included to increase specificity (16).
ecause most patients treated with trastuzumab were
reated from 2005 onward, we reported cumulative inci-
ence of HF or CM up to 3 years after breast cancer
iagnosis.
ancer characteristics, comorbidities, and socioeconomic
tatus. SEER data includes the following breast cancer
haracteristics: stage, grade, tumor size, and number of
ositive lymph nodes. Use of radiation therapy was ascer-
ained from Medicare claims (17). Breast surgery was
lassified into mastectomy or breast conserving according to
CD-9-CM codes (Online Appendix). Comorbidities were
ategorized using the Elixhauser method (14), which pro-
ides slightly better discrimination compared with other
omorbidity classifications (18,19). Comorbidities were
dentified from inpatient, outpatient, and physician Medi-
are claims for specific ICD-9-CM codes at any time during
he 2 years before the breast cancer diagnosis. We also
dentified several cardiovascular risk factors, including: cor-
nary artery disease, ischemic stroke or transient ischemic
ttack, hypertension, diabetes mellitus, renal failure, atrial
brillation or atrial flutter, and hyperlipidemia, as ascer-
ained by ICD-9-CM codes and the Elixhauser method.
e used median household income from the 2000 United
tates Census according to patient zip code of residence as
proxy for socioeconomic status because patient-level data
re not available in SEER.
tatistical Analysis. Baseline patient characteristics were
ompared across the adjuvant therapy groups using the
hi-squared test. Temporal trends in use of adjuvant-
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Armitage test for binary outcomes and the Jonckheere-
Terpstra test for outcomes with more than 2 groups.
Cumulative HF or CM incidence rates were compared
across adjuvant cancer therapy groups using unadjusted
Poisson regression models, with no adjuvant therapy as the
reference group. Adjusted Poisson models then were con-
structed adjusting for potential confounders, including pa-
tient demographics (age, race, marital status), breast cancer
characteristics, cardiovascular conditions, number of Elix-
hauser comorbidities (excluding cardiovascular conditions),
year of breast cancer diagnosis, SEER registry location, and
median household income.
To evaluate generalizability to the overall Medicare pop-
ulation, we compared HF or CM incidence rates between
SEER-Medicare cancer patients without adjuvant treat-
ment against the matched cohort of cancer-free female
Medicare beneficiaries. Secondary analyses also examined
HF and CM outcomes separately. Time-to-event analyses
using Cox proportional hazards regression models were
explored, but the assumption of proportional hazards be-
tween adjuvant treatment groups did not hold; these results
were not presented.
Statistical analyses were performed using SAS software
version 9.2 (SAS, Inc., Cary, North Carolina). The Yale
Human Investigation Committee determined that this anal-
ysis did not directly involve human subjects.
Results
The SEER-Medicare cohort consisted of 45,537 women
with early-stage breast cancer. Patients were elderly, with a
median age of 76 years (mean: 76.2 years, standard devia-
tion: 6.2 years). Overall, 431 (1.0%) received trastuzumab,
431 (0.9%) received AT, 5,257 (11.5%) received
anthracycline-based chemotherapy, 2,712 (5.9%) received
other (nonanthracycline) chemotherapy, and 36,700
(80.6%) received no adjuvant chemotherapy or trastuzumab
(Table 1). The proportion of patients who received any
adjuvant chemotherapy, trastuzumab, or both remained
nearly constant across the study period, ranging from 19.8%
in 2000 to 21.6% in 2007. Of the 8,837 patients who
received any form of adjuvant therapy, the proportion of
those who received trastuzumab or AT increased from
2.6% in 2000 to 22.6% in 2007 (p  0.001) (Fig. 1).
On average, women treated with trastuzumab, AT, or
anthracycline were younger, had more Elixhauser comor-
bidities, and had fewer cardiovascular conditions compared
with patients who received no adjuvant therapy (Table 1).
Patients with breast cancer of higher stage, higher grade,
larger tumor size, greater number of positive lymph nodes,
or who underwent mastectomy were more likely to be
treated with trastuzumab, AT, or anthracycline (p 
0.001).
Three years after diagnosis from breast cancer, the ob-
served cumulative incidence of HF or CM was significantly ahigher (p  0.001) for patients receiving trastuzumab (26.7
per 100 patients) and AT (28.2 per 100 patients) com-
pared with patients who received with no adjuvant therapy
(16.9 per 100 patients) (Table 2). In unadjusted analysis,
patients who received anthracyclines were less likely to have
HF or CM compared with patients who received no
adjuvant therapy (15.3 vs. 16.9 per 100 patients, p 0.001).
he 3-year HF or CM incidence for patients who received
ther types of chemotherapy was not significantly different
rom patients who received no adjuvant therapy (17.0 vs.
6.9 per 100 patients, p  0.89).
Observed HF or CM incidence rates for women receiving
o adjuvant therapy were slightly lower compared with the
atched control group of female Medicare beneficiaries
ithout breast cancer after 3 years of follow-up (16.9 vs.
8.7 per 100 patients, p  0.001) (Table 3). However,
djusted 3-year HF or CM incidence rates were not
ignificantly different between women with breast cancer
ho did not receive adjuvant therapy compared with
atched cancer-free controls (17.2 vs. 17.2 per 100 patients,
 0.99).
In the unadjusted Poisson models, patients who received
rastuzumab had higher rates of HF or CM after 3 years of
ollow-up (incidence rate ratio [IRR]: 1.61, 95% confidence
nterval [CI]: 1.30 to 1.99) as well as those who received
T (IRR: 1.66, 95% CI: 1.36 to 2.04) compared with
atients who received no adjuvant therapy (Table 4). Pa-
ients treated with anthracyclines had a paradoxically lower
isk of HF or CM (IRR: 0.90, 95% CI: 0.83 to 0.98), and
atients treated with other chemotherapy were not signifi-
antly different in their risk of HF or CM (IRR: 1.01, 95%
I: 0.91 to 1.12) compared with patients who received no
djuvant therapy.
In the adjusted Poisson models of 3-year HF or CM
utcomes, both trastuzumab and AT were associated with
igher risk for HF or CM compared with no adjuvant
herapy (IRR: 1.78, 95% CI: 1.43 to 2.21, and IRR: 2.32,
5% CI: 1.87 to 2.87, respectively). Anthracyclines also
ere associated with a higher risk of HF or CM (IRR: 1.12,
5% CI: 1.02 to 1.23), whereas other chemotherapy treat-
ents were not associated with different risks compared
ith no adjuvant therapy (IRR: 1.06, 95% CI: 0.95 to 1.18).
isk of HF or CM increased across each age category.
ther factors associated with a higher risk of HF or CM
ncluded black race, higher comorbidity score, history of
oronary artery disease, stroke or transient ischemic attack,
iabetes mellitus, hypertension, renal failure, and atrial
brillation or atrial flutter.
The adjusted cumulative incidence rates of HF or CM
ncreased throughout the 3 years after cancer diagnosis
Table 2). Women receiving adjuvant therapy of trastu-
umab, AT, or anthracycline therapy had significantly
igher cumulative incidence rates of HF or CM compared
ith those receiving no adjuvant therapy at 1, 2, and 3 years
fter diagnosis (p  0.001). The addition of trastuzumab to
nthracycline was estimated to increase the number of HF
2508 Chen et al. JACC Vol. 60, No. 24, 2012
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All Breast
Cancer
Patients Trastuzumab
Anthracycline

Trastuzumab Anthracycline
Other
Chemotherapy None p Value
Cancer-free
Patients
p Value
vs. None
Total sample 45,537 (0) 437 (0) 431 (0) 5,257 (0) 2,712 (0) 36,700 (0) 36,700 (0)
Age group (yrs)
67–69 7,550 (16.6) 74 (16.9) 153 (35.5) 1,902 (36.2) 608 (22.4) 4,813 (13.1) 0.001 5,003 (13.6) 0.081
70–74 12,534 (27.5) 153 (35.0) 184 (42.7) 2,082 (39.6) 978 (36.1) 9,137 (24.9) 9,154 (24.9)
75–79 12,109 (26.6) 100 (22.9) 77 (17.9) 1,047 (19.9) 740 (27.3) 10,145 (27.6) 9,900 (27.0)
80–94 13,344 (29.3) 110 (25.2) 17 (3.9) 226 (4.3) 386 (14.2) 12,605 (34.3) 12,643 (34.4)
Race
White 41,560 (91.3) 387 (88.6) 376 (87.2) 4,668 (88.8) 2,403 (88.6) 33,726 (91.9) 0.001 31,332 (85.4) 0.001
Black 2,266 (5.0) 28 (6.4) 29 (6.7) 368 (7.0) 202 (7.4) 1,639 (4.5) 2,240 (6.1)
Other 1,711 (3.8) 22 (5.0) 26 (6.0) 221 (4.2) 107 (3.9) 1,335 (3.6) 3,128 (8.5)
Elixhauser score
0 29,810 (56.7) 296 (24.3) 296 (16.2) 3,813 (13.8) 1,841 (24.0) 23,564 (66.2) 0.001 23,564 (64.2) 0.001
1–2 13,951 (35.1) 123 (47.4) 124 (49.7) 1,322 (61.3) 785 (61.9) 11,597 (29.1) 11,597 (31.6)
3 1,776 (8.1) 18 (28.4) 11 (34.1) 122 (25.0) 86 (14.0) 1,539 (4.7) 1,539 (4.2)
Pre-existing cardiovascular
conditions
CAD 1,873 (4.1) 16 (3.7) 16 (3.7) 202 (3.8) 118 (4.4) 1,521 (4.1) 0.76 1,704 (4.6) 0.001
Stroke/TIA 2,298 (5.0) 17 (3.9) 16 (3.7) 183 (3.5) 96 (3.5) 1,986 (5.4) 0.001 2,100 (5.7) 0.067
Diabetes 7,635 (16.8) 79 (18.1) 69 (16.0) 890 (16.9) 524 (19.3) 6,073 (16.5) 0.005 6,366 (17.3) 0.004
Hypertension 26,399 (58.0) 260 (59.5) 233 (54.1) 2,770 (52.7) 1,536 (56.6) 21,600 (58.9) 0.001 21,586 (58.8) 0.92
Renal failure 551 (1.2) 11 (2.5) 11 (2.6) 45 (0.9) 30 (1.1) 454 (1.2) 0.005 454 (1.2) 0.001
Atrial fibrillation/flutter 3,255 (7.1) 26 (5.9) 15 (3.5) 190 (3.6) 187 (6.9) 2,837 (7.7) 0.001 2,409 (6.6) 0.001
Hyperlipidemia 22,988 (50.5) 257 (58.8) 239 (55.5) 2,646 (50.3) 1,406 (51.8) 18,440 (50.2) 0.001 16,427 (44.8) 0.001
Stage
I 25,832 (56.7) 106 (24.3) 70 (16.2) 724 (13.8) 652 (24.0) 24,280 (66.2) 0.001
II 16,002 (35.1) 207 (47.4) 214 (49.7) 3,221 (61.3) 1,679 (61.9) 10,681 (29.1)
III 3,703 (8.1) 124 (28.4) 147 (34.1) 1,312 (25.0) 381 (14.0) 1,739 (4.7)
Grade
1: Well differentiated 10,812 (23.7) 21 (4.8) 11 (2.6) 514 (9.8) 309 (11.4) 9,957 (27.1) 0.001
2: Moderately
differentiated
19,370 (42.5) 111 (25.4) 98 (22.7) 1,953 (37.2) 1,008 (37.2) 16,200 (44.1)
3: Poorly differentiated 11,577 (25.4) 274 (62.7) 291 (67.5) 2,371 (45.1) 1,174 (43.3) 7,467 (20.3)
4: Undifferentiated;
anaplastic
485 (1.1) 13 (3.0) 11 (2.6) 100 (1.9) 37 (1.4) 324 (0.9)
Unknown 3,293 (7.2) 18 (4.1) 20 (4.6) 319 (6.1) 184 (6.8) 2,752 (7.5)
Tumor size (cm)
2.0 28,030 (61.6) 140 (32.0) 136 (31.6) 1,710 (32.5) 1,074 (39.6) 24,970 (68.0) 0.001
2.0–5.0 14,852 (32.6) 236 (54.0) 220 (51.0) 2,761 (52.5) 1,398 (51.5) 10,237 (27.9)
5.0 2,279 (5.0) 47 (10.8) 54 (12.5) 685 (13.0) 219 (8.1) 1,274 (3.5)
Missing 376 (0.8) 14 (3.2) 21 (4.9) 101 (1.9) 21 (0.8) 219 (0.6)
No. positive lymph nodes
None 28,709 (63.0) 203 (46.5) 132 (30.6) 1,553 (29.5) 1,161 (42.8) 25,660 (69.9) 0.001
1–3 7,767 (17.1) 103 (23.6) 144 (33.4) 1,954 (37.2) 982 (36.2) 4,584 (12.5)
4 3,642 (8.0) 103 (23.6) 125 (29.0) 1,537 (29.2) 461 (17.0) 1,416 (3.9)
None examined 5,211 (11.4) 17 (3.9) 17 (3.9) 155 (2.9) 88 (3.2) 4,934 (13.4)
Unknown 208 (0.5) 11 (2.5) 13 (3.0) 58 (1.1) 20 (0.7) 106 (0.3)
Surgery
Breast conserving 26,067 (57.2) 188 (43.0) 163 (37.8) 2,083 (39.6) 1,223 (45.1) 22,410 (61.1) 0.001
Mastectomy 19,470 (42.8) 249 (57.0) 268 (62.2) 3,174 (60.4) 1,489 (54.9) 14,290 (38.9)
Radiation therapy
Right side 12,199 (26.8) 116 (26.5) 119 (27.6) 1,580 (30.1) 737 (27.2) 9,647 (26.3) 0.001
Left side 12,598 (27.7) 117 (26.8) 135 (31.3) 1,740 (33.1) 767 (28.3) 9,839 (26.8)
None 20,740 (45.5) 204 (46.7) 177 (41.1) 1,937 (36.8) 1,208 (44.5) 17,214 (46.9)Values are n (%). Cell sizes smaller than 11 are suppressed per Surveillance, Epidemiology, and End Results-Medicare policy.
CAD  coronary artery disease; TIA  transient ischemic attack.
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1, 2, and 3 years of follow-up, respectively (p  0.001).
ompared with no adjuvant therapy, trastuzumab without
nthracycline chemotherapy was estimated to increase the
umber of HF or CM cases by 9.7, 10.4, and 14.1 per 100
atients after 1, 2, and 3 years of follow-up, respectively
p  0.001).
In secondary analyses examining 3-year HF and CM
ncidence separately, AT was associated significantly with
F alone (IRR: 1.65, 95% CI: 1.27 to 2.13) and CM alone
IRR: 8.18, 95% CI: 5.56 to 12.06) compared with no
djuvant therapy in the adjusted models. Trastuzumab
ithout anthracycline chemotherapy was borderline signif-
cantly associated with HF alone (IRR: 1.28, 95% CI: 0.98
o 1.66) and was associated significantly with CM alone
IRR: 6.43, 95% CI: 4.29 to 9.64) compared with no
djuvant therapy.
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Cumulative Incidence of Heart Failure or Cardiomyopathy During FiTable 2 Cumulative Incidence of Heart Failure or Cardiomyopat
All Cancer
Patients
Anthracycline  Trastuzuma
(n  431)
Observed cumulative incidence
1 year 7.2 16.4*†
2 years 12.3 23.8*†
3 years 16.9 28.2*†
Adjusted cumulative incidence
1 year 7.5 22.0*†
2 years 13.3 33.2*†
3 years 18.7 41.9*†Values are %. Per 100 patients if surviving for the full time. Poisson model used to measure significance.
odel containing anthracycline plus trastuzumab and anthracycline adjuvant therapy. ‡p  0.05 versusDiscussion
The use of trastuzumab in the adjuvant setting for breast
cancer increased substantially in the Medicare population
from 2000 through 2007. Compared with patients who
received no adjuvant chemotherapy or trastuzumab, use of
trastuzumab was associated with an absolute 14.0% higher
adjusted incidence rate for HF or CM over 3 years. Patients
who received both trastuzumab and anthracycline had an
absolute 23.8% higher rate, and those treated with anthra-
cycline chemotherapy alone has an absolute 2.1% higher rate
of HF or CM events over 3 years.
Intrinsic differences in the mechanisms of cardiotoxicity
may be one explanation for why the risk of developing HF
or CM was higher with trastuzumab than with anthracy-
cline therapy. Cardiac damage resulting from anthracycline
therapy is thought to be the result of free radical injury and
oxidative stress, resulting in permanent myocyte loss (20),
2004 2005 2006 2007 
ancer Diagnosis 
Trastuzumab Other Chemotherapy 
–2008
apy, or trastuzumab among patients who received any adjuvant therapy
Years After Diagnosis by Cancer Therapyuring First 3 Years After Diagnosis by Cancer Therapy
Anthracycline
(n  5,257)
Trastuzumab
(n  437)
Other Chemotherapy
(n  2,712)
None
(n  36,700)
7.7‡ 15.7* 7.8 6.8
11.9 20.7* 12.4 12.1
15.3‡ 26.7* 17.0 16.9
9.8* 16.7* 8.4* 7.0
15.3* 23.2* 13.7* 12.8
20.2‡ 32.1* 19.2 18.103 
ast C
umab 
2000
otherrst 3hy D
b*p  0.001 versus no adjuvant therapy group. †p  0.001 versus anthracycline group, only in the
no adjuvant therapy group.
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naling pathways essential for myocyte function. Alterna-
tively, our findings also may reflect differences in patient
selection if clinicians were more careful to select the lowest-
risk patients for anthracycline, given that cardiotoxicity
results in permanent cell damage. Our finding that anthra-
cycline therapy was associated with a lower risk of HF or
CM in unadjusted analyses suggests that some selection did
occur, but after adjustment, the relationship between treat-
ment and HF or CM became positive, as expected.
Differences in the frequency of follow-up assessment of
left ventricular function also may explain in part why
patients treated with trastuzumab had higher rates of HF or
CM, because more frequent ascertainment of LVEF allows
for greater opportunity to detect declines in systolic func-
tion. The National Comprehensive Cancer Network guide-
lines suggest periodic assessment of LVEF during the
course of trastuzumab therapy at baseline, 3, 6, and 9
months (21); in contrast, for chemotherapy, typically a
baseline LVEF assessment is performed with follow-up
assessments made on the basis of symptoms. As such, HF or
CM rates may seem to be higher in patients treated with
trastuzumab because of additional detection of asymptom-
atic patients. However, secondary analyses demonstrated an
association between trastuzumab and AT with HF alone
without CM. Because of the symptomatic nature of HF, it
would be less likely to be influenced by intensity of follow-up
LVEF assessment compared with the combined HF or CM
outcome.
Our estimates of the increased relative rate of HF or CM
associated with adjuvant therapy are consistent with a prior
study by Du et al. (22) that reported an increased risk of HF
associated with trastuzumab (hazard ratio: 1.97) and with
AT (hazard ratio: 2.37) relative to no adjuvant therapy for
women with breast cancer in the SEER-Medicare database
from 1998 through 2005. An important distinction is that
our study focused on the use of trastuzumab in the adjuvant
Cumulative Incidence of HeartFailure or Cardiomyopathy During theirst 3 Years in Breast Cancer Patients WithoutAdj vant The apy Versus Cancer-Fre Controls
Table 3
Cumulative Incidence of Heart
Failure or Cardiomyopathy During the
First 3 Years in Breast Cancer Patients Without
Adjuvant Therapy Versus Cancer-Free Controls
Breast Cancer,
No Adjuvant Therapy
(n  36,700)
Cancer-Free
Medicare Controls
(n  36,700)
Observed
1 year 6.8 8.0*
2 year 12.1 13.7*
3 year 16.9 18.7*
Adjusted
1 year 6.7 7.0
2 year 12.2 12.4
3 year 17.2 17.2
Values are %. Per 100 patients if surviving for the full time. Poisson model used to measure
significance. Adjusted for age, race, Elixhauser score, and pre-existing cardiovascular conditions.
*p  0.001.setting, similar to the randomized clinical trials, whereas Du iet al. included women with metastatic (stage IV) disease for
whom HF or CM risk is a less important concern relative to
the potential benefit of improved survival. Our findings also
were comparable with those from a meta-analysis of 5
trastuzumab trials by Viani et al. (23) that reported an odds
ratio of 2.45 associated with trastuzumab versus standard
adjuvant therapy (predominately anthracycline chemotherapy).
However, it is important to consider that the absolute risk
of HF or CM associated with trastuzumab in our study was
substantially higher than those reported from 4 major
randomized clinical trials of trastuzumab. The proportion of
patients with severe HF (New York Heart Association
classes III or IV) in these studies ranged from 2% to 4% in
the trastuzumab plus standard adjuvant therapy arms over
3.0 to 5.4 years of follow-up and less than 1% in the control
standard adjuvant therapy arms that consisted largely of
anthracycline chemotherapy (5–7). In contrast, the observed
3-Year Unadjusted and Adjusted IncidenceRat Ratios for Heart Failure or CardiomyopathyTable 4 3-Y ar Unadjusted and Adjusted IncidenceRate Ratios for Heart Failure or Cardiomyopathy
IRR 95% CI p Value
Unadjusted
Chemotherapy/biologic therapy
Trastuzumab 1.61 1.30–1.99 0.001
Anthracycline  trastuzumab 1.66 1.36–2.04 0.001
Anthracycline 0.90 0.83–0.98 0.014
Other chemotherapy 1.01 0.91–1.12 0.80
None (ref) 1.00 1.00–1.00 NA
Adjusted
Chemotherapy/biologic therapy
Trastuzumab 1.78 1.43–2.21 0.001
Anthracycline  trastuzumab 2.32 1.87–2.87 0.001
Anthracycline 1.12 1.02–1.23 0.021
Other chemotherapy 1.06 0.95–1.18 0.30
Age group (yrs)
67–69 (reference) 1.00 1.00–1.00 NA
70–74 1.15 1.05–1.27 0.003
75–79 1.40 1.28–1.54 0.001
80–94 1.98 1.80–2.17 0.001
Race
White (reference) 1.00 1.00–1.00 NA
Black 1.22 1.10–1.35 0.001
Other 0.74 0.62–0.88 0.001
Elixhauser score
0 (reference) 1.00 1.00–1.00 NA
1 to 2 1.49 1.41–1.57 0.001
3 1.98 1.80–2.18 0.001
Pre-existing cardiovascular conditions
CAD 1.54 1.41–1.69 0.001
Stroke/TIA 1.26 1.16–1.38 0.001
Diabetes 1.63 1.54–1.73 0.001
Hypertension 1.33 1.26–1.41 0.001
Renal failure 1.88 1.62–2.19 0.001
Atrial fibrillation of flutter 2.35 2.19–2.51 0.001
Hyperlipidemia 0.93 0.88–0.98 0.010
Adjusted model also includes year of diagnosis; Surveillance, Epidemiology, and End Results
registry; median income; and breast cancer characteristics.CI  confidence interval; IRR  incident rate ratio; NA  not applicable; other abbreviations as
n Table 1.
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were considerably higher, at 26.7 and 28.2 per 100 patients
for trastuzumab and AT, respectively, and 15.3 per 100
patients for anthracycline. Although these 3-year HF or
CM incidence rates seem high, they must be considered in
the context of the baseline HF or CM rates in the female
cancer-free Medicare cohort (observed 3-year HF or CM
incidence of 18.7 per 100 patients). However, comparisons
of HF or CM rates from clinical trials remain challenging
because the definition of cardiotoxicity events vary consid-
erably (24), and it is likely that the sensitivity and specificity
of HF or CM events between clinically based and claims-
based assessments also differ.
The absolute incremental risk of HF or CM attributable
to adding trastuzumab to anthracycline therapy was sub-
stantially higher for SEER-Medicare patients compared
with those of clinical trial cohorts consisting of younger
patients. The absolute incremental difference in HF or CM
between AT and anthracycline alone was 17.9 per 100
patients over 2 years in the SEER-Medicare population. In
comparison, a meta-analysis of 4 trastuzumab trials reported
an absolute incremental increase of 1.6 per 100 patients for
New York Heart Association classes III and IV HF and an
absolute incremental increase of 7.2 per 100 patients for
CM over an average of 2 years of follow-up (8). It is not
surprising that HF or CM rates in the SEER-Medicare
population were substantially higher compared with the
clinical trials. The incidence of HF or CM is known to
increase with age (25), and the SEER-Medicare population
was considerably older than subjects in the trastuzumab
clinical trials. In addition, the clinical trials excluded pa-
tients at high risk for HF or CM developing, such as
individuals with prior HF, coronary artery disease, arrhyth-
mias, poorly controlled hypertension, or valve disease (5,26).
That the clinical trials consisted primarily of low-risk
cardiac patients illustrates the usefulness of a registry-based
approach to estimate cancer treatment-associated HF or
CM rates in the general population.
Our results indicated that patients with breast cancer who
did not receive adjuvant therapy had a slightly lower risk of
HF or CM developing compared with matched controls of
female Medicare beneficiaries without breast cancer. This
should not be interpreted to indicate that breast cancer is
protective against HF or CM, but rather, this reflects that
women who are diagnosed with breast cancer differ in subtle
respects from the general population. Most women who are
diagnosed with early-stage breast cancer have received the
diagnosis as a result of screening mammography, and such
patients also are likely to engage in other preventative
behaviors that concurrently reduce risk of HF or CM, such
as blood pressure or diabetes screening. After adjusting for
age, race, and comorbidities, there was no significant dif-
ference in 3-year HF or CM incidence between the no
adjuvant therapy group and matched cancer-free controls.
Our findings illustrate that the incidence of HF or CM is
high for older women in general, regardless of the presenceof breast cancer. This suggests that there is a potentially
important role for cardiologists before initiation of cancer
therapy to optimize patients who are at high risk for
developing HF or CM and to detect early signs and
symptoms of HF or CM after treatment. Ongoing research
evaluating the role of cardiac biomarkers for predicting risk
of HF or CM during cancer therapy may prove useful for
identifying patients who may benefit from early cardiology
referral (27).
Study limitations. Our study is limited in that HF and
CM events and comorbidities were ascertained on the basis
of administrative codes and were not confirmed clinically.
Estimates of HF incidence estimated from Medicare data
(28) typically have been higher than those from prospective
surveillance cohorts, such as the Framingham Heart Study
(29). This may reflect several factors, such as differences in
stringency for criteria defining HF or an administrative
coding practice of using rule-out diagnoses as indications.
However, administrative codes for HF and cardiovascular
comorbidities have high specificity (approximately 95%) and
positive predictive value (95%) (30–33). Second, informa-
tion on dose and method of administration for the adjuvant
cancer therapies in our study currently is not considered
reliable in Medicare claims. Third, clinical data on left
ventricular systolic function were not available; as a result,
neither the severity of CM nor differentiation of systolic
from diastolic HF could be established; future studies using
clinical data to differentiate systolic and diastolic HF are
warranted. Fourth, although we controlled for a number of
cardiac and noncardiac risk factors, we cannot rule out the
potential for residual confounding where healthier women
were more likely to undergo adjuvant therapy. Furthermore,
data on medication use in the SEER-Medicare database
were limited, which may introduce residual confounding if
cardiovascular therapies such as -blockers (34) and
ngiotensin-converting enzyme inhibitors (27) reduce risk
f adjuvant therapy HF or CM and if use of these therapies
aried significantly by treatment group.
onclusions
n a cohort of older female Medicare beneficiaries with
reast cancer, use of trastuzumab increased by more than
-fold from 2000 through 2007 among patients receiving
ny form of adjuvant therapy. The absolute incremental risk
f adding trastuzumab to anthracycline for older SEER-
edicare patients was substantially higher than that re-
orted from clinical trials enrolling younger, healthier
omen.
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